SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 80 filers reported holding SPERO THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 2.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $105,000 | -49.0% | 12,015 | -6.6% | 0.00% | 0.0% |
Q4 2021 | $206,000 | -15.6% | 12,860 | -2.9% | 0.00% | 0.0% |
Q3 2021 | $244,000 | +29.1% | 13,245 | -2.3% | 0.00% | 0.0% |
Q2 2021 | $189,000 | +8.0% | 13,559 | +13.8% | 0.00% | 0.0% |
Q1 2021 | $175,000 | -23.9% | 11,916 | +0.3% | 0.00% | 0.0% |
Q4 2020 | $230,000 | +132.3% | 11,885 | +34.4% | 0.00% | – |
Q3 2020 | $99,000 | -16.8% | 8,840 | +0.4% | 0.00% | -100.0% |
Q2 2020 | $119,000 | +91.9% | 8,802 | +15.4% | 0.00% | – |
Q1 2020 | $62,000 | -7.5% | 7,626 | +8.9% | 0.00% | – |
Q4 2019 | $67,000 | -8.2% | 7,003 | +1.7% | 0.00% | – |
Q3 2019 | $73,000 | -2.7% | 6,888 | +5.7% | 0.00% | – |
Q2 2019 | $75,000 | +15.4% | 6,514 | +28.1% | 0.00% | – |
Q1 2019 | $65,000 | +91.2% | 5,084 | -8.4% | 0.00% | – |
Q4 2018 | $34,000 | -42.4% | 5,548 | -0.8% | 0.00% | – |
Q3 2018 | $59,000 | -7.8% | 5,591 | +28.7% | 0.00% | – |
Q2 2018 | $64,000 | +16.4% | 4,345 | +12.7% | 0.00% | – |
Q1 2018 | $55,000 | +14.6% | 3,857 | -5.1% | 0.00% | – |
Q4 2017 | $48,000 | – | 4,063 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
XTX Topco Ltd | 58,368 | $70,625 | 0.01% |